Skip to content

comparison of Injectable platelet rich fibrin and steroids in oral lichen planus

Comparative efficacy of injectable platelet rich fibrin and triamcinolone acetonide in symptomatic oral lichen planus

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/11/060372
Enrollment
75
Registered
2023-11-30
Start date
Unknown
Completion date
Unknown
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D899- Disorder involving the immune mechanism, unspecified Health Condition 2: K137- Other and unspecified lesions of oral mucosa

Interventions

Intervention1: injectable platelet rich fibrin: Injectable platelet rich fibrin at a interval of 7 days for 8 weeks or till the lesion disappear, whatever is earlier Control Intervention1: injectable

Sponsors

PGIDS Rohtak
Lead Sponsor
PGIDS Rohtak
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1)Clinically symptomatic and histologically proven cases of oral lichen planus in accordance to WHO criteria. 2)Patient who give written consent to participate in the study

Exclusion criteria

Exclusion criteria: )Patient under the age of 18 years. 2)Histopathological signs of moderate to severe dysplasia. 3)Patients with genital or cutaneous involvement. 4)History of topical or systemic corticosteroids therapy within one month prior to recruitment. 5)Allergic or contraindication to administration of injectable corticosteroids. 6)Patients with Hb levels 7)Patients with known hematological disease, chronic liver disease and psychiatric disorders. 8)Smokers or chewable tobacco users. 9)Patients with pregnancy or lactating mothers.

Design outcomes

Primary

MeasureTime frame
1)To evaluate and compare the size of lesion in both the groups. 2)To evaluate and compare the healing of lesion after the treatment in both the groups Timepoint: 1)BASELINE,1 MONTH, 6 MONTHS

Secondary

MeasureTime frame
)Change in intensity of pain score. 2)To assess patient satisfaction. 3)To evaluate the need of alternative treatment modalities. 4) To evaluate the side effects of injectable platelet rich fibrin, if any Timepoint: baseline, 1month,3months,6months

Countries

India

Contacts

Public ContactYogita

PGIDS, Rohtak

drambika79@rediffmail.com9315903300

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026